Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis

References

• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• EngholmGFJChristensenNKejsAMTNORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries: association of the Nordic Cancer registriesDanish Cancer Society2016
   Google Scholar
• DabestaniSThorstensonALindbladPHarmenbergULjungbergBLundstamSRenal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld J Urol20163481081108626847337
   PubMed Web of Science ®Google Scholar
• CoppinCPorzsoltFKumpfJColdmanAWiltTImmunotherapy for advanced renal cell cancerCochrane Database Syst Rev20003Cd00142510908496
   PubMedGoogle Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• LjungbergBBensalahKCanfieldSEAU guidelines on renal cell carcinoma: 2014 updateEur Urol201567591392425616710
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncologyKidney Cancer, version 2.20162016
   Google Scholar
• Regionalt cancercentrumNational Swedish guidelines, Renal cell carcinoma 2017Nationellt vårdprogram Njurcancer 20172017 Available from: http://cancercentrum.se/samverkan/cancerdiagnoser/urinvagar/njurcancer/vardprogram/Accessed February 01, 2019 Swedish
   Google Scholar
• GeynismanDMHuJCLiuLTina ShihYCTreatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United StatesClin Genitourin Cancer2015132e93e10025450038
   PubMedGoogle Scholar
• MarounRMaunouryFBenjaminLNachbaurGDurand-ZaleskiIIn-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French National Hospital database from 2008 to 2013PLoS One2016119e016286427649305
   PubMed Web of Science ®Google Scholar
• SoerensenAVDonskovFKjellbergJHealth economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA Study 2Eur Urol201568351652225533417
   PubMed Web of Science ®Google Scholar
• WilkingNWilkingUJönssonBThe positioning of economic principles under the changing conditions of the novel drug developmental process in cancerChin Clin Oncol2014322325841419
   PubMedGoogle Scholar
• RemákECharbonneauCNégrierSKimSTMotzerRJEconomic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinomaJ Clin Oncol200826243995400018711190
   PubMed Web of Science ®Google Scholar
• HoyleMGreenCThompson-CoonJCost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinomaValue Health2010131616819804430
   PubMed Web of Science ®Google Scholar
• HengDYChiKNMurrayNA population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerCancer2009115477678319127560
   PubMed Web of Science ®Google Scholar
• PalSKNelsonRAVogelzangNDisease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy eraPLoS One201385e6334123658823
   PubMed Web of Science ®Google Scholar
• Schlesinger-RaabATreiberUZaakDHölzelDEngelJMetastatic renal cell carcinoma: results of a population-based study with 25 years follow-upEur J Cancer200844162485249518783939
   PubMed Web of Science ®Google Scholar
• ShekDTomlinsonBBrownMBrunsonAPanCXLaraPNEpidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a Registry analysis of 28,252 patientsClin Genitourin Cancer2012102939822382008
   PubMed Web of Science ®Google Scholar
• SoerensenAVDonskovFHermannGGImproved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish renal cancer Group (DARENCA) study-2Eur J Cancer201450355356224215846
   PubMed Web of Science ®Google Scholar
• VaishampayanUVankayalaHVigneauFDThe effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry databaseClin Genitourin Cancer201412212412924225251
   PubMed Web of Science ®Google Scholar
• WahlgrenTHarmenbergUSandströmPTreatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)Br J Cancer201310871541154923531701
   PubMed Web of Science ®Google Scholar
• LindskogMWahlgrenTSandinROverall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populationsUrol Oncol2017359541.e15541541
   PubMed Web of Science ®Google Scholar
• BeislandCJohannesenTBKleppOOverall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based studyOnco Targets Ther20171037138528144152
   PubMed Web of Science ®Google Scholar
• BarlowLWestergrenKHolmbergLTalbäckMThe completeness of the Swedish Cancer register: a sample survey for year 1998Acta Oncol2009481273318767000
   PubMed Web of Science ®Google Scholar
• WettermarkBHammarNMichaelforedCThe new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiol Drug Saf200716772673516897791
   PubMed Web of Science ®Google Scholar
• LudvigssonJFAnderssonEEkbomAExternal review and validation of the Swedish national inpatient registerBMC Public Health201111145021658213
   PubMed Web of Science ®Google Scholar
• KaplanELMeierPNonparametric estimation from incomplete observationsJ Am Stat Assoc195853282457481
   Web of Science ®Google Scholar
• LinDYFeuerEJEtzioniRWaxYEstimating medical costs from incomplete follow-up dataBiometrics19975324194349192444
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study GroupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• BjarnasonGAKhalilBHudsonJMOutcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literatureUrol Oncol201432448048724321258
   PubMed Web of Science ®Google Scholar
• JonaschESlackRSGeynismanDMPhase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinomaJ Clin Oncol201836161588159329641297
   PubMed Web of Science ®Google Scholar
• BracardaSIacovelliRBoniLSunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the rainbow analysisAnn Oncol201526102107211326216384
   PubMed Web of Science ®Google Scholar
• NajjarYGMittalKElsonPA 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinomaEur J Cancer20145061084108924559686
   PubMed Web of Science ®Google Scholar
• AtkinsonBJKalraSWangXClinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedulesJ Urol2014191361161824018239
   PubMed Web of Science ®Google Scholar
• KondoTTakagiTKobayashiHSuperior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-offJpn J Clin Oncol201444327027724474815
   PubMed Web of Science ®Google Scholar
• KalraSRiniBIJonaschEAlternate sunitinib schedules in patients with metastatic renal cell carcinomaAnn Oncol20152671300130425628443
   PubMed Web of Science ®Google Scholar
• LeeJLKimMKParkIRandomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: restore trialAnn Oncol201526112300230526347107
   PubMed Web of Science ®Google Scholar
• DonskovFvon der MaaseHImpact of immune parameters on long-term survival in metastatic renal cell carcinomaJ Clin Oncol200624131997200516648500
   PubMed Web of Science ®Google Scholar
• LagunaMPRe: health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA Study 2J Urol2016195360860926887702
   PubMed Web of Science ®Google Scholar
• SwallowEMessaliAGhateSMcdonaldEDuchesneauEPerezJRThe additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinomaJ Manag Care Spec Pharm201824433534329578848
   PubMed Web of Science ®Google Scholar
• BenedictAFiglinRASandströmPEconomic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinomaBJU Int2011108566567221265994
   PubMed Web of Science ®Google Scholar
• Thompson CoonJHoyleMGreenCBevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluationHealth Technol Assess20101421184iiiiv
   PubMed Web of Science ®Google Scholar
• BurströmKSunSGerdthamUGSwedish experience-based value sets for EQ-5D health statesQual Life Res201423243144223975375
   PubMed Web of Science ®Google Scholar
• FrankeRHKaulJDThe Hawthorne experiments: first statistical interpretationAm Sociol Rev1978435623643
   Web of Science ®Google Scholar
• BraunholtzDAEdwardsSJLilfordRJAre randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”J Clin Epidemiol200154321722411223318
   PubMed Web of Science ®Google Scholar
• PeppercornJMWeeksJCCookEFJoffeSComparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured reviewLancet2004363940526327014751698
   PubMed Web of Science ®Google Scholar
• TartariFSantoniMBurattiniLMazzantiPOnofriABerardiREconomic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challengesCancer Treat Rev201648202427310708
   PubMed Web of Science ®Google Scholar
• MckayRRBosséDChoueiriTKEvolving systemic treatment landscape for patients with advanced renal cell carcinomaJ Clin Oncol2018JCO201879025336153623
   Google Scholar
• FlippotREscudierBAlbigesLImmune checkpoint inhibitors: toward new paradigms in renal cell carcinomaDrugs201878141443145730187355
   PubMed Web of Science ®Google Scholar